House passes FDA’s $6.4 billion fee plan for drug reviews
The $6.4 billion accord that Teva Pharmaceutical Industries Inc. (TEVA), Johnson & Johnson (JNJ) (JNJ) and other companies reached with U.S. regulators to fund new medicine and device reviews through 2017 passed the House of Representatives. The House voted late yesterday 387-5 in favor of the legislation, which is similar to a measure approved by […]